France· FR:66127361
OCREVUS 300 mg, solution à diluer pour perfusion
A medicinal product containing ocrélizumab, registered in France by ROCHE REGISTRATION (ALLEMAGNE).
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- OCRÉLIZUMAB
- Manufacturer
- ROCHE REGISTRATION (ALLEMAGNE)
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- No
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
- cip1334009550483671 flacon en verre de 10 mL
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Ocrélizumab in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandOcrevusRoche Registration GmbH
- CzechiaOCREVUSRoche Registration GmbH, Grenzach-Wyhlen
- United KingdomOcrevus 300mg/10ml concentrate for solution for infusion vialsRoche Products Ltd
- BelgiumOcrevus 300 mgRoche Registration
- SwitzerlandOcrevus subkutan 920 mg/23 ml, InjektionslösungRoche Pharma (Schweiz) AG
- SpainOCREVUS 300 MG CONCENTRADO PARA SOLUCION PARA PERFUSIONRoche Registration Gmbh
- IcelandOcrevusRoche Registration GmbH*
- NetherlandsOcrevus 300 mg concentraat voor oplossing voor infusieRoche Registration GmbH
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Ocrevus
- Liechtenstein · Ocrevus
- Norway · Ocrevus
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/7cd3ae95-f7a8-448c-af3e-50c46c0d3685 GET /v1/drugs/7cd3ae95-f7a8-448c-af3e-50c46c0d3685?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "66127361",
"date_amm": "2018-01-08",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/17/1231",
"substance": "OCRÉLIZUMAB",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "solution à diluer pour perfusion",
"voies_administration": "intraveineuse",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about ocrélizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.